Related Experiment Video
Updated: Jan 19, 2026

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag
Published on: December 14, 2017
Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic
Roy N Alcalay1, Frank Hsieh2, Elizabeth Tengstrand2
1Columbia University, Department of Neurology, New York, New York, USA.
Background:
LRRK2 mutations are a common cause of dominantly inherited PD. Previous studies showed decreases in urine levels of didocohexaenoyl (22:6) bis(monoacylglycerol)phosphate in LRRK2-knockout mice and in non-human primates treated with LRRK2 kinase inhibitors. We hypothesized that urine levels of bis(monoacylglycerol)phosphate isoforms will be higher in individuals with a PD-causing gain-of-kinase function mutation, LRRK2 G2019S. The objective of this study was to investigate alterations in urinary phospholipids as biomarkers of LRRK2 mutations and Parkinson's disease status/phenotypes.
Methods:
Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was used to assess 54 bioactive phospholipids in urine from the LRRK2 Cohort Consortium (n = 80). To confirm and extend the findings, urine from an independent LRRK2 cohort from Columbia University Irving Medical Center (n = 116) was used. Both cohorts were composed of LRRK2 G2019S carriers and non-carriers with and without PD.
Results:
In each cohort, 4 bis(monoacylglycerol)phosphate isoforms (di-18:1-bis[monoacylglycerol]phosphate, didocohexaenoyl [22:6] bis[monoacylglycerol] phosphate, 2,2'-di-22:6-bis[monoacylglycerol]phosphate, and 2,2'-di-18:1-bis[monoacylglycerol]phosphate) were significantly higher (2.5- to 4.3-fold) in G2019S carriers compared with non-carriers. Interestingly, 2,2'-di-18:1-bis(monoacylglycerol)phosphate levels were marginally higher in LRRK2 carriers with PD than in those without PD (P = 0.045). Moreover, increased 2,2' and total di-22:6-bis(monoacylglycerol)phosphate were associated with worse cognitive status assessed by the Montreal Cognitive Assessment (P = 0.0033 and 0.0144, respectively).
Conclusions:
The observed association of bis(monoacylglycerol)phosphate isoforms with LRRK2 G2019S mutation, PD status among G2019S carriers, and correlation with cognitive decline suggest the potential use of urinary bis(monoacylglycerol)phosphate isoforms as biomarkers for clinical trials of LRRK2-targeted therapies. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Insights
Urinary bis(monoacylglycerol)phosphate levels are elevated in individuals with the LRRK2 G2019S mutation, a common cause of Parkinson's disease (PD). These findings suggest potential biomarkers for LRRK2-targeted therapies.
Area of Science:
- Biochemistry
- Genetics
- Neuroscience
Background:
- Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are a frequent cause of inherited Parkinson's disease (PD).
- Previous research indicated reduced urinary levels of specific phospholipids in LRRK2-deficient models and treated non-human primates.
- This study investigated urinary bis(monoacylglycerol)phosphate (BMP) isoforms as potential biomarkers for LRRK2 mutations and PD.
Purpose of the Study:
- To determine if urinary BMP isoform levels are higher in individuals carrying the PD-associated LRRK2 G2019S mutation.
- To explore the utility of urinary phospholipids as biomarkers for LRRK2 mutations and Parkinson's disease phenotypes.
Main Methods:
- Utilized ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) to analyze 54 bioactive phospholipids in urine samples.
- Examined two independent cohorts: the LRRK2 Cohort Consortium (n=80) and a cohort from Columbia University Irving Medical Center (n=116).
- Included participants with and without PD, who were either LRRK2 G2019S carriers or non-carriers.
Main Results:
- Four specific BMP isoforms were found to be significantly elevated (2.5- to 4.3-fold) in G2019S carriers compared to non-carriers in both cohorts.
- A marginal increase in 2,2'-di-18:1-BMP was observed in LRRK2 carriers with PD versus those without PD (P=0.045).
- Elevated levels of 2,2'-di-22:6-BMP and total di-22:6-BMP correlated with poorer cognitive status, as measured by the Montreal Cognitive Assessment.
Conclusions:
- Urinary BMP isoforms show a strong association with the LRRK2 G2019S mutation.
- These phospholipid alterations may serve as valuable biomarkers for assessing PD status in G2019S carriers and monitoring cognitive decline.
- The findings support the potential use of urinary BMP isoforms as biomarkers in clinical trials targeting LRRK2 therapies.
More Related Videos
07:53Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
Related Concept Videos
08:55Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag
Electron Carriers
Over the many stages of cellular respiration, glucose breaks down into carbon dioxide and water. Electron carriers pick up electrons lost by glucose in these reactions, temporarily storing and releasing them into the electron...
07:53Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
08:56Development of New Therapeutic Applications Using Microfluidics
Filtration and Urine Formation